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Interventions to improve delivery of isoniazid
preventive therapy: an overview of systematic
reviews
Lisa V Adams1*, Elizabeth A Talbot1, Karen Odato2, Heather Blunt2 and Karen R Steingart3
Abstract
Background: Uptake of isoniazid preventive therapy (IPT) to prevent tuberculosis has been poor, particularly in the
highest risk populations. Interventions to improve IPT delivery could promote implementation. The large number of
existing systematic reviews on treatment adherence has made drawing conclusions a challenge. To provide
decision makers with the evidence they need, we performed an overview of systematic reviews to compare
different organizational interventions to improve IPT delivery as measured by treatment completion among those
at highest risk for the development of TB disease, namely child contacts or HIV-infected individuals.
Methods: We searched the Cochrane Database of Systematic Reviews, the Database of Abstracts of Reviews of
Effects (DARE), and MEDLINE up to August 15, 2012. Two authors used a standardized data extraction form and the
AMSTAR instrument to independently assess each review.
Results: Six reviews met inclusion criteria. Interventions included changes in the setting/site of IPT delivery, use of
quality monitoring mechanisms (e.g., directly observed therapy), IPT delivery integration into other healthcare
services, and use of lay health workers. Most reviews reported a combination of outcomes related to IPT adherence
and treatment completion rate but without a baseline or comparison rate. Generally, we found limited evidence to
demonstrate that the studied interventions improved treatment completion.
Conclusions: While most of the interventions were not shown to improve IPT completion, integration of
tuberculosis and HIV services yielded high treatment completion rates in some settings. The lack of data from high
burden TB settings limits applicability. Further research to assess different IPT delivery interventions, including those
that address barriers to care in at-risk populations, is urgently needed to identify the most effective practices for IPT
delivery and TB control in high TB burden settings.
Keywords: Tuberculosis, HIV, Adherence, Latent tuberculosis infection
Background
Treating latent tuberculosis infection (LTBI) with isonia-
zid preventive therapy (IPT) in persons who are at high
risk for developing tuberculosis (TB) has been shown to
decrease progression to TB disease and improve survival
[1-4]. Consequently, the World Health Organization rec-
ommends a six-month course of IPT for children younger
than five years who are close contacts to an adult with
sputum smear-positive TB, and HIV-infected adults and
children older than 12 months who are unlikely to have
TB disease [5].
Despite clear international recommendations, only 8%
to 20% of eligible children actually receive IPT [6]. Stud-
ies in HIV-infected populations show similarly low rates
of IPT provision [7,8]. Possible reasons for this low up-
take include imperfect TB/HIV care coordination for
many HIV-infected IPT candidates and a past focus on
TB disease diagnosis rather than prevention. There is
also a lack of programmatic guidelines to identify IPT
candidates, sensitive methods to exclude TB disease, and
patient management tools to ensure LTBI treatment
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completion. Even if patients are initiated on IPT, benefit
is only realized if patients complete their prescribed
therapy. While barriers to IPT adherence can exist at
both programmatic and patient levels, TB control pro-
grams have long recognized the need to move beyond
specific patient factors and encompass broader health
system changes to optimize individual patient care and
outcomes.
Medication adherence is a complex human behavior,
and the medical and social science literature on this
topic is extensive. In such cases – where hundreds of
published studies exist on an issue – systematic reviews
are typically performed to formulate precise questions
and to consolidate, appraise and evaluate the evidence to
facilitate decision making by clinicians and policy
makers. In the case of treatment adherence, several sys-
tematic reviews have examined the effectiveness of dif-
ferent interventions to improve adherence in various
medical conditions [9-14], including tuberculosis [15,16].
Some reviews have focused on a specific intervention
with patients, such as counseling and patient education
[12-15], while others have looked at system changes in
regimen schedules and pill packaging [11]. Several re-
cent systematic reviews have focused on interventions
specifically to improve IPT adherence, such as the use of
lay health workers [9], patient education and counseling
[15], and incentives and enablers [16].
Given the many strategies that could potentially im-
prove medication adherence, determining the attribut-
able effects and summarizing the findings of the many
studies that have evaluated these different strategies
would be difficult. To provide focus, in their overview of
reviews, van Dulmen and colleagues have described the-
oretical approaches to adherence and categorized inter-
ventions on patient adherence for different medical
conditions [17]. The authors define seven categories of
adherence interventions: technical (e.g., changes in pack-
aging), behavioral (e.g., use of reminders), educational (e.
g., providing information to individual patients), affective
(e.g., provider empathy), social support (e.g., practical or
emotional support), structural (e.g., establishing a care
program in the workplace) and complex or multi-faceted
(e.g., some combination of the above) [17]. With treat-
ment completion serving as our patient important out-
come, we sought interventions in IPT delivery most
likely to improve adherence among individual patients.
Interventions related to the delivery, practice, and
organization of health care services have also been catego-
rized by the Cochrane Effective Practice and Organisation
of Care (EPOC) Group [18]. Under the EPOC taxonomy,
the category “organizational interventions” are those inter-
ventions that involve “a change in who delivers health care,
how care is organized, or where care is delivered” [18]. This
category of interventions fits a health system’s approach to
support adherence. With treatment completion as the ul-
timate goal of IPT delivery, organizational interventions
that can be undertaken by a national TB program to affect
IPT adherence may have the greatest impact. Mapping in-
terventions to the EPOC group taxonomy ensures valid
comparisons of findings are made.
With the large number of systematic reviews already
performed on interventions to improve treatment adher-
ence generally and IPT adherence specifically, the chal-
lenge persists of how to integrate, assess, compare and
contrast the evidence from these reviews to facilitate
clinical and programmatic decision-making. In this in-
stance, the best approach is to summarize the reviews in
one place by performing an overview of systematic re-
views. As described by Smith et al., overviews of system-
atic reviews are the appropriate next step to provide
clinical decision makers with the comprehensive infor-
mation that they need [19].
Therefore, we conducted an overview of systematic re-
views that assessed interventions to improve adherence
of IPT in high-risk individuals to better inform decision
making on IPT delivery. Specifically, we sought to com-
pare different organizational interventions to improve
IPT delivery as measured by treatment completion
among those at highest risk for the development of TB
disease, namely child contacts or HIV-infected individ-
uals. This focused review question allowed us to concen-
trate on interventions that a national TB program can
most easily influence. To the best of our knowledge, no
such overview has been performed. These findings are
intended to inform public health professionals and
policy makers from high TB burden countries where IPT
delivery by programs, uptake by patients, and treatment
completion rates are suboptimal. Improved worldwide
delivery of IPT could reduce global morbidity and mor-
tality from TB, especially among children and HIV-
infected individuals.
Objective
Our objective was to synthesize and compare the evi-
dence from systematic reviews examining the effect of
organizational interventions on IPT delivery among
those at highest risk for the development of TB
disease.
Methods
We followed the Cochrane Collaboration recommenda-
tions for performing overviews of systematic reviews as
described in the Cochrane Handbook [20].
Criteria for considering reviews for inclusion
Types of reviews: We included all systematic reviews writ-
ten in English, Spanish, and French that met our selection
criteria and were identified by our search strategies. We
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excluded narrative reviews and systematic reviews that did
not include acceptable study designs (i.e., randomized con-
trolled trials, quasi-randomized controlled trials, controlled
before-and-after studies, interrupted time series or before-
and-after studies); and evaluate at least one of the specified
organizational interventions; or measure treatment
completion.
Types of participants: Although our population of
interest was child contacts and HIV-infected individuals,
we included systematic reviews of all persons for whom
treatment of LTBI is recommended regardless of age
and HIV infection [21,22]. We broadened inclusion be-
cause we anticipated there would be limited data on
child contacts and HIV-infected individuals. We in-
cluded systematic reviews that focused primarily on or-
ganizations and health systems.
Types of interventions
Interventions related to the delivery, practice, and
organization of health care services have been catego-
rized into four groups by the Cochrane Effective Practice
and Organisation of Care (EPOC) Group: professional,
financial, organizational, and regulatory [18]. We se-
lected organizational interventions because these are the
interventions most feasible for TB control program im-
plementation, can be instituted without the need for
considerable additional financial inputs, and are ex-
pected to be the most commonly practiced and studied
interventions to improve IPT delivery. We included one
provider-oriented intervention, the revision of profes-
sional roles, since this also seemed a feasible activity for
a national TB program to undertake. Other types of in-
terventions are not typically under the purview of the
TB control program. The organizational, predominantly
structural, interventions we considered most relevant to
IPT delivery are listed in Table 1. We included reviews
evaluating these interventions, or combinations of these
interventions. We excluded financial and regulatory
interventions.
Types of outcomes
The primary outcome of interest was treatment comple-
tion rate (TCR). We defined TCR as the percentage of
patients who initiated IPT and took at least 80% of pre-
scribed doses within a nine-month period. We also in-
cluded TCR as defined by the authors of the review. IPT
was defined as INH monotherapy taken at any dose for
at least six months to treat LTBI.
Search strategy
We searched the following databases without date re-
strictions on August 15, 2012: the Cochrane Database of
Systematic Reviews (Cochrane Library 2012 issue 8), the
Database of Abstracts of Reviews of Effects (DARE)
(Cochrane Library 2012 issue 8) and MEDLINE
(PubMed). To identify systematic reviews in MEDLINE,
we used PubMed's Systematic Review filter. We searched
for citations in all languages; however, due to available
resources, we restricted the articles for inclusion to
those published in English, French, or Spanish.
We employed two search strategies (Additional file 1):
the first included indexed terms and text words related
to latent tuberculosis and its drug therapies. Due to the
similarities between IPT and co-trimoxazole for primary
prevention of opportunistic infections in HIV-infected
persons in terms of duration and target population, we
also searched for systematic reviews that evaluated the
delivery of co-trimoxazole preventive therapy. Therefore,
the second strategy included indexed terms and text
words related to HIV, pneumocystis pneumonia, and co-
trimoxazole preventive therapy. Additionally, one author
hand-searched reviews and overviews in four Cochrane
review groups (Cochrane Infectious Diseases Group,
Cochrane Effective Practice and Organisation of Care
Group, Cochrane Public Health Group, Cochrane Con-
sumers and Communication Review Group) and DARE
databases through June 2012. We also checked reference
lists of selected papers for additional reviews.
Selection of reviews
Two authors independently scrutinized non-duplicate ti-
tles and abstracts identified by literature searching to
identify potentially eligible reviews. Any citation identi-
fied by either author was included in a second screen
during which the full text was reviewed. The same re-
view authors independently assessed the reviews for in-
clusion using pre-specified inclusion and exclusion
criteria. Any disagreements were resolved by discussion.
One review author selected reviews identified by hand-
searching the Cochrane database.
Data collection and analysis
We developed a standardized data extraction form to
summarize key characteristics of the reviews. One au-
thor piloted the form with two reviews and finalized the
form. Then two authors independently extracted data on
the following characteristics: objectives, study designs of
included studies, participants, setting, country, interven-
tions, outcomes, and review quality. Any disagreements
in data extraction were resolved by discussion or deci-
sion of a third author. We did not contact review or
study authors for additional information due to resource
constraints.
Quality assessment
We used the AMSTAR instrument to assess methodo-
logical quality of each review [29]. We did not assess the
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Table 1 Mapping of the included reviews to the selected cochrane effective practice and organisation of care group organizational interventionsa








This intervention could include providing IPT outside of
the usual TB clinic setting, such as in an HIV care and
treatment center for HIV-infected patients or in the
household through home-based care programs for TB
child contacts or in another community-based setting.
Introduction of IPT to community settings
such as methadone clinics or shelters (Al-
Darraji et al, 2012 [23] and DeFulio et al, 2012




et al, 2012 [24];
Uyei et al, 2011 [25]
Overall, high levels of adherence and a range of




This intervention might include changing from paper to








Quality monitoring mechanisms may include monitoring
of medication or treatment outcomes.
Provision of directly observed therapy (DOT)
for LTBI (Hirsch-Moverman et al, 2008 [26];
Zuñiga et al, 2012 [27])
Hirsch-Moverman
et al, 2008 [26];
Zuñiga et al, 2012
[27]
While higher adherence was observed with DOT
than self-administered therapy, actual comple-
tion rates in comparative studies remain subopti-
mal—as low as 44% to at best 80% (Hirsch-
Moverman et al, 2008 [26]).
Revision of
professional roles,
e.g., nurses and lay
health workers
(1 review)
This intervention includes shifts in the roles among
caregivers, also known as ‘professional substitution’ or
shifting boundaries in professional care [28].
Use of lay health care workers for peer
supported self-supervision or DOT
Lewin et al, 2010
[9]
There was moderate quality evidence that this
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incorporating IPT delivery into other health care services
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quality of the individual studies in the reviews but noted
any assessment by the review authors.
Role of the funding source
The funding source for this work did not influence the
study design, interpretation of data, writing of the re-
port, or the decision to submit the paper for publication.
Results
Our search yielded a total of 589 citations, with an add-
itional nine systematic reviews identified from a review of
the references of the selected reviews and one by hand-
searching the Cochrane database. Figure 1 details our
search and selection process. We selected reviews that,
based on our inclusion criteria, included at least one
organizational intervention (based on the EPOC taxonomy)
to improve IPT or co-trimoxazole adherence. We identified
six reviews that met our criteria. All assess IPT delivery;
none of the co-trimoxazole adherence reviews identified
met our intervention criteria.
Of the six selected reviews (involving a total of 105 stud-
ies), one was a Cochrane review [9] and five were non-
Cochrane reviews [23-27]. The specific interventions in this
overview mapped to the EPOC taxonomy are presented in
Table 1. Extracted data from the six included reviews are
shown in Table 2.
The six systematic reviews assessed different interven-
tions to improve IPT adherence and, in some cases,
adherence with diagnostic testing and other treatments.
Hirsch-Moverman et al. also aimed to identify predictors of
adherence and Zuñiga et al. to identify correlates of IPT ad-
herence in Hispanic patients. In assessing these two re-
views, we focused on the effect of the interventions. Four of
the six reviews assessed studies of IPT adherence that were
conducted predominantly in the US [9,23,26,27], or the US
and Canada [26], or the US, Spain (four studies) and
Singapore (one study) [23], the latter being a high-income
country with a TB incidence rate of 50/100,000 [30]. The
most common study designs reported by the review au-
thors were observational (30 studies), randomized con-
trolled trials (19 studies), and prospective cohort (15
studies).
The AMSTAR ratings of the included reviews ranged
from 4 to 10 out of a maximum of 11 (Table 3). Only one
review was rated as high quality (AMSTAR score of 10)
and three reviews were rated as lower quality (AMSTAR
ratings of less than seven). Only two reviews reported on
methodological quality of the included studies [9,25]. In
Figure 1 PRISMA Flow Diagram. Legend: The PRIMSA diagram details our search and selection process applied during the overview.
Adams et al. BMC Infectious Diseases 2014, 14:281 Page 5 of 10
http://www.biomedcentral.com/1471-2334/14/281





Study settings (no. of studies










improve IPT delivery in
correctional facilities
Jails and prisons (18) Adults US, Spain,
Singapore
6% Median TCR 44% (3-87%); low
TCRs among RCTs (23, 12 and
12%)
Behavior of incarcerated






Review use of incentives on
medication adherence





US, Timor-Leste 20% TCR improved in 2 of 3 studies
(44% v. 26% and 92% v. 82%);
1 showed no effect










To identify predictors of
adherence and adherence
interventions
Jails, refugee camp, homeless

















To assess the effects of lay
health worker interventions
in primary and community
health care on maternal
and child health and the
management of infectious
diseases





US 0% Little to no effect on treatment
completion (RR = 1 · 0)
No children under age 5
included, 20% HIV-
infected in one study,




To examine the effect of











100% High adherence (75-92%);






To synthesize data on LTBI
treatment adherence in
Hispanic populations in the
US
Clinics and public health
programs dispensing LTBI
treatment (12)
Hispanic adults US 0% Self-reports of LTBI adherence
may be inaccurate; power
dynamic impedes patient and
healthcare provider
communication; direct
measures of adherence will
improve validity of results
No children included;
adult Hispanic
populations only, no HIV
data
aHigh TB incidence defined as TB incidence > 30/100,000.






































































Al-Darraji X X X X X X
DeFulio X X X X
Hirsch-
Moverman
X X X X X X
Lewin X X X X X X X X X X
Uyei X X X X X X X X X





















Lewin et al., two of 82 studies addressed IPT delivery; the
review authors judged that one of these studies had ad-
equate sequence generation but was not blinded. The other
study only addressed incomplete data adequately. Neither
study had sufficient data for the review authors to deter-
mine the risk of bias due to allocation concealment or free-
dom from selective reporting. In Uyei et al., the authors’
general appraisal of the quality of studies noted the absence
of randomization and that missing data were addressed in
only two of the included studies.
Participants
All six reviews assessed studies that enrolled adults, and
two reviews included children or adolescents (1 of 5
[20%] studies in Defulio et al. and 1 of 4 [25%] in Lewin
et al.). Studies of IPT adherence in the US were focused
on the populations that are at the highest risk for treat-
ment non-adherence, namely intravenous drug users
[9,23,24,26], incarcerated individuals [9,24,27], homeless
individuals [23,27], and recent immigrants [24,25].
Three reviews specified that HIV-infected individuals
were included in any of the included studies (9 of 18
[50%] studies in Al-Darraji et al., 9 of 78 [12%] in
Hirsch-Moverman and 56 of 56 [100%] in Uyei et al.)
[23,25,26].
Interventions
The majority of interventions examined in the studies of
the included systematic reviews were changes in the set-
ting/site of service delivery. Three reviews assessed
studies of integration of IPT delivery into other health
care services, either community-based care [23,24] or
HIV care [25]. One review assessed studies that exam-
ined the impact of a revision of professional roles, spe-
cifically the use of lay health workers to support self-
administered IPT or provide directly observed therapy
[9]. Two reviews assessed the impact of providing dir-
ectly observed therapy [26,27], while one also looked for
additional correlational relationships related to side-
effects, social support, demographics, education, and
self-report of health [27].
Outcomes
Most reviews reported outcomes related to IPT adher-
ence and TCR (Table 2). Only one review provided a
clear definition of treatment completion, defining it as
the ingestion of at least 80% of prescribed doses [25].
The authors of this review stated that, to allow compari-
sons across studies, they calculated TCR as the number
completing treatment over the number initiating treat-
ment. Another review calculated TCR as the percentage
of patients who completed “six months of treatment
within the study’s follow-up period” [25]. Most reviews
provided only the post-intervention TCR (i.e., without
the pre-intervention rate). Collectively, there was little
evidence to demonstrate that most of the interventions
studied had a positive impact on TCRs.
Discussion
This overview is the first published assessment of the
evidence of organizational interventions to improve IPT
adherence. Among the reviews that assessed studies of
IPT adherence in high-risk US populations, none of the
interventions examined were found to be effective at
improving IPT adherence or TCR. The systematic re-
view by Uyei et al. that included only studies from high
TB-burden, low-income settings examined the impact
of TB and HIV service integration. While IPT adherence
was reportedly high across the six studies in this review,
the TCRs were variable. In addition, the lack of com-
parison groups in these studies makes it difficult to as-
sess if TB and HIV service integration was the main
driver of the benefit.
Beyond setting, the applicability of the evidence from
these systematic reviews based on patient population is un-
certain. While our populations of interest were child con-
tacts and HIV-infected individuals, most reviews assessed
IPT adherence in adult populations, with only two reviews
including children in no more than one-quarter of their in-
cluded studies [9,24]. Similarly, only three reviews included
HIV-infected persons, although with greater representation
among the included studies (12% - 100%) [23,25,26].
We found that the quality of the systematic reviews in
this overview varied. The low quality of the majority of re-
views suggests limitations in design and/or execution that
may undermine conclusions about the results of the
reviews.
We also recognize that there are other as yet unstud-
ied interventions or combinations of interventions that
might improve IPT adherence. In their overview of re-
views of interventions focused on improving consumers’
use of non-IPT medication, Ryan et al. examined self-
monitoring and self-management, simplification of dos-
ing, and involvement of pharmacists [31]. While they
found several interventions that showed promise in im-
proving adherence, none were consistently effective
across diseases, populations, or settings. It is unclear
whether their findings are applicable to IPT because
none of the reviews they evaluated specifically addressed
IPT.
Although the contribution of educational and coun-
seling sessions to adherence was not the primary object-
ive of this overview, we extracted these data when
available. Two reviews that met inclusion for our over-
view (that were not included in Ryan et al.) assessed the
use of education and/or counseling as a means of im-
proving treatment adherence in a number of settings
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[23,26]. Both included studies of IPT delivery but nei-
ther found a demonstrable improvement in adherence.
A recent Cochrane review by M’Imunya et al. specific-
ally assessed the role of patient education and counsel-
ing in promoting adherence to TB treatment and LTBI
treatment [15]. They conclude that the LTBI TCR may
increase, but they emphasize that benefits from patient
education and counseling vary with context and the
underlying reasons for poor adherence. Therefore, any
educational intervention must be tailored to the setting
and population, and there is unlikely to be a universally
beneficial approach.
We also recognize that adverse reactions and how they
are managed are important to patients and can reduce
adherence and treatment completion. Adverse reactions
and their impact on treatment completion could not be
systematically addressed in our overview as this would
have required a different methodology. Nonetheless, we
looked for and summarized adverse drug reactions when
data were provided in the included reviews. While four
of the six review authors sought to collect this data, only
two reported any data on the frequency of adverse
events. In both reviews, the reported rates were very low
(median <5%) [23,27].
There are limitations to our overview. While the
search strategy included all languages, we included only
reviews published in English, French, and Spanish, and
therefore may have missed papers that were published in
other languages. However, of 589 citations initially iden-
tified, only 25 (4%) papers were excluded based on lan-
guage. There was some overlap across the reviews that
examined specific populations, namely US residents who
were homeless, using intravenous drugs, and/or in
prison (8 of 105 total studies [8%] appeared in more
than one review). One study of Hispanic patients was in-
cluded in two reviews (1/105, 1%).
Conclusions
Overall, while most organizational interventions did not
consistently result in improvements in IPT completion,
the integration of TB and HIV services yielded
high TCRs in some settings. The lack of data on
organizational interventions to improve IPT delivery in
high burden TB settings and in the high-risk popula-
tions of interest makes it difficult to draw conclusions
applicable to populations in these settings. This notable
absence of data is, however, a clear indication of the
need for additional investigation in these settings and
these populations. Further research to assess different
IPT delivery interventions, including those that address
barriers to care in at-risk populations, is urgently
needed to identify the most effective practices for IPT
delivery and TB control in high TB-burden settings.
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